About Us
SINAPPS stands for Study of Immunology in Antibody Positive Psychosis. We are a research group formed of collaborating Universities in the UK, investigating the role of autoimmune antibodies as a cause of psychosis.
SINAPPS2 TRIAL MANAGEMENT GROUP
Find out more about our group members by clicking on their names.
Professor Alasdair Coles Chief Investigator and Principal Investigator, University of Cambridge
Professor Belinda Lennox Principal investigator, University of Oxford
Professor Peter Jones, Co-investigator, University of Cambridge
Professor Eileen Joyce, Co-investigator, University College London
Dr Michael Zandi , Principal Investigator, UCL Hospitals NHS Trust, London
Professor Ly-Mee Yu, Lead Trial Statistician, University of Oxford
Dr Thomas Kabir, Head of Public Involvement,
Dr Ksenija Yeeles, SINAPPS Project Manager, University of Oxford
Mr Francis Dowling, Senior Trial Coordinator, Cambridge Clinical Trial Unit
SINAPPS2 Trial PRINCIPAL Investigators
Dr Timothy Harrower, Royal Devon & Exeter Wonford Hospital, Exeter
Dr Akram Hosseini, Queen's Medical Centre, Nottingham
Dr Ester Coutinho, King's College Hospital, London
Dr Nazar Sharaf, Salford Royal Hospital, Salford
Dr Priya Shanmugarajah, Royal Hallamshire Hospital, Sheffield
Dr Saif Huda, The Walton Centre, Liverpool
Dr John Goodfellow, Queen Elizabeth University Hospital, Glasgow
SINAPPS2 Researchers
Isobel Harrison, Research Fellow/Senior Research Nurse
Jane Hainsworth, Research Coordinator, research-administrative support
Florence Hallett, Research Assistant
Brendan Sargent, Clinical Research Fellow